11/07/2023 - General information
The Tatiana Foundation Prize for Young Researchers, awarded by the Spanish Society of Neurosciences, aims to identify and support the future leaders of Spanish neuroscience research. Valero, coordinator of the Neural Computation Laboratory at the Hospital del Mar Research Institute, has made extraordinary discoveries that have changed the way neuroscientists think about how local neural microcircuits represent spatial information. The award will be presented next September at the XI World Congress of the International Brain Research Organization (IBRO) to be held in Granada and organized by the Spanish Society of Neurosciences.
29/06/2023 - General information
The project, jointly coordinated by UPF professor Ferran Sanz, has enjoyed the participation of numerous members of the GRIB; the UPF research programme in Medical Bioinformatics and the Hospital del Mar Research Institute, as well as the spinoff Med Bioinformatics Solutions, which emerged from the same programme. eTRANSAFE, the European project to share data on the safety of medicines, has come to fruition. On a single platform, the project has integrated data from more than 10,000 pharmacological studies by reference pharmaceutical companies, from a dozen databases that amass public and private information of clinical and preclinical studies. The project has also developed 'Flame', an open-source machine learning application that allows predicting whether future drugs will have adverse effects.
Més informació "Culmination of the eTRANSAFE project to share data on the safety of medicines"
28/06/2023 - General information
The Mutua Madrileña Foundation has awarded its XX Health Research Grants, worth 2.3 million euros, to 26 clinical studies that will be carried out in hospitals throughout Spain. Six of these research projects will be carried out in Barcelona in the areas of cancer immunotherapy, rare childhood diseases, infant and juvenile mental health and transplantation, and together receive funding of more than 680,000 euros. From the Hospital del Mar Research Institute, Doctor Joaquín Arribas, will carry out a study in the field of immunotherapy in cancer. Specifically, it will perform a prospective analysis of biopsies obtained in a phase 1 clinical trial of dose increase using CAR-t Her 2 biospecific cells in patients with advanced solid tumors positive for P95HER2.
21/06/2023 - Press release
The Molecular Mechanisms of Cancer and Stem Cell Research Group of the Hospital del Mar Research Institute is the only center in Spain to participate in an international study that validates the deficiency of a protein, IκBα, as a marker of poor prognosis in this type of tumor The work, published in Cell Reports Medicine, has analyzed data from more than 2,000 patients. In addition, the researchers have identified one of the pathways on which this protein acts, which makes it a possible therapeutic target The Hospital del Mar Research Institute group is already working on a model to search for possible treatments that modulate the function of this marker. It should be considered that at present there are very few therapeutic alternatives for glioma, which has a very high mortality rate
15/06/2023 - Press release
A study published in iScience, spearheaded by the Hospital del Mar Research Institute and the Barcelonaβeta Brain Research Centre, part of the Pasqual Maragall Foundation, validates these tools for monitoring potential sufferers. Data was analysed from 56 volunteers who participated in the PENSA study, designed to determine whether it is possible to slow cognitive decline in stages prior to the onset of dementia through a combination of a lifestyle intervention programme and the consumption of a preparation based on a green tea component. It was possible to monitor the evolution of the cognitive functions of these people much more closely and continuously than with standard tests. This paves the way for the adaptation, practically in real time, of treatments that can be adjusted to changes in cognitive decline.
14/06/2023 - General information
The Epidemiology and Public Health Program (EPISAP) of the Hospital del Mar Research Institute held its annual meeting on June 7, where the strategic research lines of the groups were shared and the strengths of the program were analyzed. It is worth mentioning the participation in the program of young talented researchers. A consolidated research trajectory together with emerging lines, such as those derived from the COVID-19 pandemic, were highlighted at the meeting. Funding has been received for European projects in areas such as personalized prevention of suicide and depression, measurement of patient reported outcomes (PROs) and the impact on occupational health and safety associated with digital platforms.
Més informació "Annual Meeting of the Epidemiology and Public Health Program"
01/06/2023 - General information
The genomics service of FIMIM, MARGenomics, has recently incorporated the Applied Biosystems GeneChip 3000 Dx v2, a cutting-edge microarray platform funded by the Carlos III Health Institute (ISCIII) and the European Union's NextGenerationEU program. The GeneChip 3000 Dx v2 system holds the distinction of being the first microarray platform in Europe and the United States with regulatory authorization for diagnostic use, thanks to its IVD-R (In Vitro Diagnosis Regulation) certification. This significant development has enabled us to enhance our microarray services by introducing a platform specifically designed for diagnostic purposes, while continuing to offer our traditional gene expression microarray services for experimental research.
Més informació "MARGenomics launches a new microarray platform with IVD-R certification"
02/05/23 - Institutional news
The Anti-Doping Laboratory of Catalonia was visited last week by a delegation of the Board of Directors of the Catalan Association of Sports Directors (ACDE). ACDE is an association that brings together leaders, federations and professionals in the world of sport in Catalonia while providing them with the best tools to develop their role and promote excellence in the management and values of sport. The delegation was formed by Pere Sust (President of ACDE), Jordi Durá (Secretary), Francisco Sanahuja, Miquel Torres, Pilar Xifré, Manuel Martínez and Judith Martínez, all of them with extensive and recognized links to Catalan and international sports federations and organizations, and was received by the IMIM management and the Laboratory management. After an introduction of the activities of IMIM and the Laboratory, the attendees visited the Laboratory facilities
18/05/2023 - General information
The PROMES-U project aims to improve the mental health of undergraduate students by analyzing the factors that may influence the onset of mental health problems, as well as the implementation and evaluation of online interventions for the promotion of mental health and the prevention of depression and anxiety problems. Follow-up data collection began last May 4 among students who filled out the baseline survey just one year ago, with an email being sent to those who gave up their email address. Upon completion of the questionnaire, they receive a personalized report on their mental health, as well as recommendations on healthy habits and available resources. The data collected will help to improve knowledge about the mental health of students at the university.
Més informació "Data collection is started with the PROMES-U follow-up questionnaire."
30/03/2023 - Press release
Adding a peptide, a molecule made of several amino acids, to oxaliplatin, a chemotherapy drug used to treat colorectal cancer, avoids the side effects this treatment can have on normal cells, including potential chemotherapy resistance. This is confirmed by an article published in the Journal of Medicinal Chemistry, led by the Hospital del Mar Medical Research Institute and the Institute for Research in Biomedicine (IRB Barcelona). This work is the second part of a recent study that explored how platinum accumulation in normal cells promotes platinum resistance in colorectal cancer cells. This new approach prevents healthy cells surrounding the tumour from accumulating platinum. This avoids the activation of certain genes linked to poor treatment response and tumour progression.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact